TOMDF (Todos Medical) Notes Receivable: $0.00 Mil (As of Sep. 2022)


What is Todos Medical Notes Receivable?

Todos Medical TOMDF -90.00% Notes Receivable is $0.00 Mil as of Sep. 2022.

Todos Medical's Notes Receivable for the quarter that ended in Sep. 2022 was $0.00 Mil.

Todos Medical Notes Receivable Historical Data

* Premium members only.

The historical data trend for Todos Medical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Todos Medical Notes Receivable Chart

Todos Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Todos Medical Quarterly Data
Dec15 Dec16 Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Todos Medical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Todos Medical (TOMDF) has a Notes Receivable of $0.00 Mil as of Sep. 2022. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Todos Medical and its competitors.
Is Todos Medical's Notes Receivable too high?
Todos Medical's current Notes Receivable is $0.00 Mil.
How does Todos Medical's Notes Receivable compare to NDRA and IDXG?
Todos Medical's Notes Receivable of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Todos Medical and its competitors. Todos Medical's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Todos Medical stock overvalued right now?
Todos Medical (TOMDF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Todos Medical (TOMDF), the current Notes Receivable is $0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Todos Medical Business Description

Address 121 Derech Menachem Begin, 30th Floor, Tel Aviv, ISR, 6701203
Todos Medical Ltd is an in vitro diagnostics company. Its operating segments are Breast Cancer Test, Alzheimer's, and COVID-19 testing. The company generates all of its revenue from the United States.